Biotech startups that raised Series B in Boston, Massachusetts
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Superluminal Medicines | Boston | Series B | $65.5M | 2026-09-03 |
| Precede Biosciences | Boston | Series B | $63.5M | 2026-01-12 |
| VideaHealth | Boston | Series B | $40.0M | 2025-01-28 |
| GRO Biosciences | Boston | Series B | $60.3M | 2024-07-19 |
| Cardurion Pharmaceuticals | Boston | Series B | $260.0M | 2024-07-16 |
| Elion Therapeutics | Boston | Series B | $81.0M | 2024-06-17 |
| Sware | Boston | Series B | $6.0M | 2024-06-06 |
| DermBiont | Boston | Series B | $35.2M | 2023-10-19 |
8 rows of the CSV in 5 of its 18 columns.
- The 40 biotech startups in Boston, Massachusetts whose last round is Series B have raised $3.7B in total.
- 5 of them closed their most recent round in the last 12 months, $399.2M combined.
- The largest of those rounds is Soufflé Therapeutics' $135.0M Series B, dated October 2026.
- Insight Partners is an investor in 2 of them, more than any other fund.
- Health care is the most common other sector, with 37 companies (92%).
- 12% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (45% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
5 of 40| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| Precede Biosciences | Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. | Biotech | Series B | $63.5M | 2026-01-12 | $140.5M | Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 | 11 to 50 | 2005 |
| VideaHealth | VideaHealth offers dentistAI software that automatically detects pathologies in dental imaging to help dentists avoid missed diagnoses. | Biotech | Series B | $40.0M | 2025-01-28 | $66.5M | Spark Capital, Zetta Venture Partners, Pillar VC +2 | 51 to 100 | 2018 |
| Cardurion Pharmaceuticals | Cardurion Pharmaceuticals develops cardiovascular therapeutics for heart failure and related diseases. | Biotech | Series B | $260.0M | 2024-07-16 | $603.1M | New Enterprise Associates, Google Ventures, Fidelity +1 | 11 to 50 | 2017 |
| Asimov | Asimov uses artificial intelligence to build tools for designing and manufacturing therapeutics. | Artificial intelligence | Series B | $175.0M | 2023-01-05 | $205.0M | Andreessen Horowitz, DCVC, Fidelity +2 | 101 to 250 | 2017 |
Table 1. Biotech startups that raised Series B in Boston, Massachusetts: the 5 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 40.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| 2 | Precede Biosciences | Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. | Biotech | Series B | $63.5M | 2026-01-12 | $140.5M | Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 | 11 to 50 | 2005 |
Table 2. Biotech startups that raised Series B in Boston, Massachusetts: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Insight Partners | Private equity firm | New York, United States | 2 | 5% | 1 | Superluminal Medicines |
| 2 | Fidelity | Investment bank | Boston, United States | 2 | 5% | ||
| 3 | New Enterprise Associates | Venture capital firm | Menlo Park, United States | 2 | 5% | ||
| 4 | RA Capital Management | Startup incubator | Boston, United States | 1 | 2% | 1 | Superluminal Medicines |
| 5 | NVentures | Corporate venture arm | Santa Clara, United States | 1 | 2% | 1 | Superluminal Medicines |
| 6 | Qatar Investment Authority | Fund of funds | Doha, Qatar | 1 | 2% | 1 | Precede Biosciences |
| 7 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 1 | 2% | 1 | Precede Biosciences |
| 8 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 1 | 2% | 1 | Precede Biosciences |
| 9 | 5AM Ventures | Venture capital firm | Menlo Park, United States | 1 | 2% | 1 | Precede Biosciences |
| 10 | Illumina Ventures | Corporate venture arm | Foster City, United States | 1 | 2% | 1 | Precede Biosciences |
| 11 | Pillar VC | Venture capital firm | Boston, United States | 1 | 2% | ||
| 12 | Innospark Ventures | Venture capital firm | Boston, United States | 1 | 2% | ||
| 13 | Spark Capital | Venture capital firm | San Francisco, United States | 1 | 2% | ||
| 14 | Zetta Venture Partners | Venture capital firm | San Francisco, United States | 1 | 2% | ||
| 15 | MIT delta v | Startup accelerator | Cambridge, United States | 1 | 2% |
Table 3. Biotech startups that raised Series B in Boston, Massachusetts: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 37 | 92% | $3.5B |
| Software | 7 | 18% | $634.1M |
| Artificial intelligence | 4 | 10% | $483.5M |
| Hardware | 2 | 5% | $54.2M |
| Commerce | 1 | 2% | $55.0M |
Table 4. Biotech startups that raised Series B in Boston, Massachusetts by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 40 | 100% | $50.0M |
Table 5. Biotech startups that raised Series B in Boston, Massachusetts by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 1 | 20% | $135.0M |
| September 2026 | 1 | 20% | $65.5M |
| January 2026 | 2 | 40% | $139.5M |
| November 2025 | 1 | 20% | $59.2M |
Table 6. Biotech startups that raised Series B in Boston, Massachusetts: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 4 | 10% | $340.0M |
| 2025 | 5 | 12% | $286.2M |
| 2024 | 6 | 15% | $598.5M |
| 2023 | 6 | 15% | $433.2M |
| 2022 | 4 | 10% | $180.5M |
| 2021 | 2 | 5% | $80.0M |
Table 7. Biotech startups that raised Series B in Boston, Massachusetts by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 5 | 12% |
| 2015 to 2019 | 17 | 42% |
| 2010 to 2014 | 8 | 20% |
| Before 2010 | 10 | 25% |
Table 8. Biotech startups that raised Series B in Boston, Massachusetts by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 8 | 21% |
| 11 to 50 | 17 | 45% |
| 51 to 100 | 8 | 21% |
| 101 to 250 | 4 | 11% |
| 501 to 1,000 | 1 | 3% |
Table 9. Biotech startups that raised Series B in Boston, Massachusetts by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in Boston, Massachusetts. On 16 November 2026 that is 40 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 5 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 40 rows: 3 have no round amount, 0 no city and 4 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Boston, Massachusetts whose last round is Series B are on the list?
- 40, in the file dated 16 November 2026. 5 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 40 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.